AI
Wednesday, June 01, 2016 12:47:14 PM
PPHM SAB'ers Drs. Brekken+Gabrilovich June16-19 WISTAR “Myeloid Suppressors” Conf. in Philadelphia. Peregrine is 1 of 4 Session Sponsors. Dr. Brekken speaking on, “PS Signaling & Immune Suppression in the Tumor Microenvironment”.
Jun16-19 2016: “WISTAR's Regulatory Myeloid Suppressor Cells Conf.”, Philadelphia
“FROM BASIC DISCOVERY TO THERAPEUTIC APPLICATION” http://myeloidsuppressors.com
“This conference will focus on the pathological functions of myeloid-derived suppressor cells, dendritic cells, macrophages and neutrophils, and provide a forum for in-depth discussion of the most pressing issues associated with the biology & clinical application of these cells. The conference will bring together scientists from academia & industry interested in the basic and translational aspects of these cells in cancer and other pathological conditions.”
OVERVIEW: Myeloid cells are comprised of populations of mature terminally differentiated macrophages, dendritic cells and neutrophils, as well as immature myeloid cells including granulocytes, monocytes, and myeloid progenitors. These cells are evolutionarily designed to protect the host from bacteria and viruses by utilizing mechanisms of innate & adaptive immunity. They are also major contributors to tissue remodeling after injuries or resolved inflammation. In cancer, chronic infections, and inflammation, these cells are undergoing extensive changes, which make them immunosuppressive, able to actively promote angiogenesis, tumor cell invasion, and formation of pre-metastatic niches. Recent data demonstrates the association of accumulation of these cells in cancer patients and clinical outcomes of the diseases. With the development of novel immunotherapeutics, it became apparent that regulatory myeloid cells play a major role in limiting therapeutic efficacy of treatment. This conference is focused on pathological functions of myeloid-derived suppressor cells, dendritic cells, macrophages and neutrophils. The specific goals of this meeting are to develop a better understanding of the mechanisms regulating the accumulation of these cells, markers that allow for detection of these cells in cancer patients and patients with chronic infections & inflammation, and approaches to therapeutic targeting of these cells.
SPONSORS: GENERAL: Genentech, J&J(Janssen-Onc); SESSION: Juno, Galera, Reata, Peregrine; DAY: Syndax
CONF. CHAIR: Dmitry Gabrilovich, MD, PhD [PPHM SAB]
Keynote: Robert A. Weinberg, Whitehead Inst. for Biomedical Research, MIT
40 Speakers, including:
Rolf A. Brekken [PPHM SAB], UTSW-MC/Dallas
Dmitry I. Gabrilovich [PPHM SAB], The Wistar Institute, Philadelphia
- - - - - - -
6-19-16/Sun.: SESSION 6 THERAPEUTIC TARGETING OF MYELOID CELLS
9:00am: “IDO, PTEN-Tregs and control of APCs...”, David Munn, Georgia Regents Univ.
9:35am: “Graft-vs-host disease (GvHD)-associated… adoptively transferred MDSCs”, Bruce Blazar, U-Minn.
10:10am: “Combination therapy of anti-PD-1 & CSF-1R inhibitor...”, Rolf Kiessling, Karolinska Inst., Stockholm
10:45am: “Phosphatidylserine Signaling & Immune Suppression in the Tumor Microenvironment”, Dr. Rolf Brekken [PPHM SAB], UTSW-MC/Dallas
- - - - - - -
6-18-16/Sat. 3:45-5:50pm: SESSION 5 - CLINICAL SIGNIFICANCE OF REGULATORY MYELOID CELLS - Sponsored by: Peregrine Pharmaceuticals
= = = = = = = = =
11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (UTSW/DUKE's Herbert K. Lyerly) http://tinyurl.com/pbof95w
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”
11-8-14 SITC'14: Ph.2 Correlative Studies data (biopsies B4/After) on 6pts, incl. KOL Dimitry Gabrilovich’s comments: http://tinyurl.com/pchzr6h
12-10-13: With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone**, Hakan Mellstedt http://tinyurl.com/mw776mk
......**A/o 9-2015, Dr. David Carbone (PPHM SAB/KOL) is President of IASLC https://www.iaslc.org/about-us/board
Jun16-19 2016: “WISTAR's Regulatory Myeloid Suppressor Cells Conf.”, Philadelphia
“FROM BASIC DISCOVERY TO THERAPEUTIC APPLICATION” http://myeloidsuppressors.com
“This conference will focus on the pathological functions of myeloid-derived suppressor cells, dendritic cells, macrophages and neutrophils, and provide a forum for in-depth discussion of the most pressing issues associated with the biology & clinical application of these cells. The conference will bring together scientists from academia & industry interested in the basic and translational aspects of these cells in cancer and other pathological conditions.”
OVERVIEW: Myeloid cells are comprised of populations of mature terminally differentiated macrophages, dendritic cells and neutrophils, as well as immature myeloid cells including granulocytes, monocytes, and myeloid progenitors. These cells are evolutionarily designed to protect the host from bacteria and viruses by utilizing mechanisms of innate & adaptive immunity. They are also major contributors to tissue remodeling after injuries or resolved inflammation. In cancer, chronic infections, and inflammation, these cells are undergoing extensive changes, which make them immunosuppressive, able to actively promote angiogenesis, tumor cell invasion, and formation of pre-metastatic niches. Recent data demonstrates the association of accumulation of these cells in cancer patients and clinical outcomes of the diseases. With the development of novel immunotherapeutics, it became apparent that regulatory myeloid cells play a major role in limiting therapeutic efficacy of treatment. This conference is focused on pathological functions of myeloid-derived suppressor cells, dendritic cells, macrophages and neutrophils. The specific goals of this meeting are to develop a better understanding of the mechanisms regulating the accumulation of these cells, markers that allow for detection of these cells in cancer patients and patients with chronic infections & inflammation, and approaches to therapeutic targeting of these cells.
SPONSORS: GENERAL: Genentech, J&J(Janssen-Onc); SESSION: Juno, Galera, Reata, Peregrine; DAY: Syndax
CONF. CHAIR: Dmitry Gabrilovich, MD, PhD [PPHM SAB]
Keynote: Robert A. Weinberg, Whitehead Inst. for Biomedical Research, MIT
40 Speakers, including:
Rolf A. Brekken [PPHM SAB], UTSW-MC/Dallas
Dmitry I. Gabrilovich [PPHM SAB], The Wistar Institute, Philadelphia
- - - - - - -
6-19-16/Sun.: SESSION 6 THERAPEUTIC TARGETING OF MYELOID CELLS
9:00am: “IDO, PTEN-Tregs and control of APCs...”, David Munn, Georgia Regents Univ.
9:35am: “Graft-vs-host disease (GvHD)-associated… adoptively transferred MDSCs”, Bruce Blazar, U-Minn.
10:10am: “Combination therapy of anti-PD-1 & CSF-1R inhibitor...”, Rolf Kiessling, Karolinska Inst., Stockholm
10:45am: “Phosphatidylserine Signaling & Immune Suppression in the Tumor Microenvironment”, Dr. Rolf Brekken [PPHM SAB], UTSW-MC/Dallas
- - - - - - -
6-18-16/Sat. 3:45-5:50pm: SESSION 5 - CLINICAL SIGNIFICANCE OF REGULATORY MYELOID CELLS - Sponsored by: Peregrine Pharmaceuticals
= = = = = = = = =
11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (UTSW/DUKE's Herbert K. Lyerly) http://tinyurl.com/pbof95w
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”
11-8-14 SITC'14: Ph.2 Correlative Studies data (biopsies B4/After) on 6pts, incl. KOL Dimitry Gabrilovich’s comments: http://tinyurl.com/pchzr6h
12-10-13: With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone**, Hakan Mellstedt http://tinyurl.com/mw776mk
......**A/o 9-2015, Dr. David Carbone (PPHM SAB/KOL) is President of IASLC https://www.iaslc.org/about-us/board
